{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:40:36Z","timestamp":1776966036290,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,23]]},"DOI":"10.7759\/cureus.107600","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:02:46Z","timestamp":1776963766000},"source":"Crossref","is-referenced-by-count":0,"title":["Myositis-Myasthenia Overlap Syndrome After Immune Checkpoint Inhibitor Treatment: A Case Report"],"prefix":"10.7759","author":[{"given":"Christopher S","family":"Awad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack C","family":"Redick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Pohlman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorabh","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21765","article-title":"Understanding the tumor microenvironment for effective immunotherapy","volume":"41","author":"Sadeghi Rad H","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O'Byrne K, Rezaei N, Kulasinghe A. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021, 41:1474-98. 10.1002\/med.21765","journal-title":"Med Res Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SM, et al.. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022, 29:3044-60. 10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195611","article-title":"Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit","volume":"11","author":"Deharo F","year":"2022","unstructured":"Deharo F, Carvelli J, Cautela J, et al.. Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit. J Clin Med. 2022, 11:5611. 10.3390\/jcm11195611","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31483-3","article-title":"Incidence and outcomes of neuromuscular immune-related adverse events in head and neck cancer patients treated with checkpoint inhibitors","volume":"15","author":"Glaubitz S","year":"2025","unstructured":"Glaubitz S, Zsch\u00fcntzsch J, Sakkas A, Scheurer M, Wilde F, Schramm A, Ebeling M. Incidence and outcomes of neuromuscular immune-related adverse events in head and neck cancer patients treated with checkpoint inhibitors. Sci Rep. 2025, 15:43261. 10.1038\/s41598-025-31483-3","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series","volume":"2024","author":"Aggarwal N","year":"2024","unstructured":"Aggarwal N, Bianchini D, Parkar R, Turner J. Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis-a case series. Case Rep Med. 2024, 2024:5399073. 10.1155\/2024\/5399073","journal-title":"Case Rep Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.4078","article-title":"Triple M: a case of Nivolumab-induced myasthenic crisis, myocarditis and myositis","volume":"94","author":"Oliveira K","year":"2020","unstructured":"Oliveira K, Stavros K, Didion J. Triple M: a case of Nivolumab-induced myasthenic crisis, myocarditis and myositis. Neurology. 2020, 94:4078. 10.1212\/WNL.94.15_supplement.4078","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101192","article-title":"Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study","volume":"50","author":"Plomp L","year":"2025","unstructured":"Plomp L, Chassepot H, Psimaras D, et al.. Features of myositis and myasthenia gravis in patients treated with immune checkpoint inhibitors: a multicentric, retrospective cohort study. Lancet Reg Health Eur. 2025, 50:101192. 10.1016\/j.lanepe.2024.101192","journal-title":"Lancet Reg Health Eur"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.08.421","article-title":"Addressing new diagnostic and treatment challenges associated with a new age of cancer\u00a0treatment","volume":"73","author":"Bischof JJ","year":"2019","unstructured":"Bischof JJ, Presley CJ, Caterino JM. Addressing new diagnostic and treatment challenges associated with a new age of cancer\u00a0treatment. Ann Emerg Med. 2019, 73:88-90. 10.1016\/j.annemergmed.2018.08.421","journal-title":"Ann Emerg Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s44201-022-00002-9","article-title":"The current state of acute oncology training for emergency physicians: a narrative review","volume":"1","author":"Bischof JJ","year":"2022","unstructured":"Bischof JJ, Caterino JM, Creditt AB, Wattana MK, Pettit NR. The current state of acute oncology training for emergency physicians: a narrative review. Emerg Cancer Care. 2022, 1:2. 10.1186\/s44201-022-00002-9","journal-title":"Emerg Cancer Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/aet2.10010","article-title":"Cognitive debiasing strategies for the emergency department","volume":"1","author":"Daniel M","year":"2017","unstructured":"Daniel M, Khandelwal S, Santen SA, Malone M, Croskerry P. Cognitive debiasing strategies for the emergency department. AEM Educ Train. 2017, 1:41-2. 10.1002\/aet2.10010","journal-title":"AEM Educ Train"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.2608","article-title":"Actual immune checkpoint inhibitor drug use in U.S. patients with cancer","volume":"40","author":"Rawji A","year":"2022","unstructured":"Rawji A, Malin J, Dacosta Byfield S, et al.. Actual immune checkpoint inhibitor drug use in U.S. patients with cancer. J Clin Oncol. 2022, 40:2608. 10.1200\/jco.2022.40.16_suppl.2608","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020","volume":"18","author":"Thompson JA","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020, 18:230-41. 10.6004\/jnccn.2020.0012","journal-title":"J Natl Compr Canc Netw"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2023.02.016","article-title":"The 2022 Model of the Clinical Practice of Emergency Medicine","volume":"64","author":"Beeson MS","year":"2023","unstructured":"Beeson MS, Bhat R, Broder JS, et al.. The 2022 Model of the Clinical Practice of Emergency Medicine. J Emerg Med. 2023, 64:659-95. 10.1016\/j.jemermed.2023.02.016","journal-title":"J Emerg Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley T","year":"2020","unstructured":"Cooksley T, Gupta A, Al-Sayed T, Lorigan P. Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer. 2020, 130:193-7. 10.1016\/j.ejca.2020.02.025","journal-title":"Eur J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386888-myositis-myasthenia-overlap-syndrome-after-immune-checkpoint-inhibitor-treatment-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:02:47Z","timestamp":1776963767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386888-myositis-myasthenia-overlap-syndrome-after-immune-checkpoint-inhibitor-treatment-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.107600","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}